CureVac NV (5CV)

49.92
-5.88(-10.54%)
  • Volume:
    448,215
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    48.00 - 55.27

5CV Overview

Prev. Close
55.8
Day's Range
48-55.27
Revenue
-
Open
54.8
52 wk Range
37.15-120.82
EPS
-
Volume
448,215
Market Cap
-
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
231,310
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
-
Next Earnings Date
Sep 01, 2021
What is your sentiment on CureVac NV?
or
Market is currently closed. Voting is open during market hours.

CureVac NV News

CureVac NV Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellSell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellBuy
SummaryNeutralStrong SellStrong SellStrong SellNeutral

CureVac NV Company Profile

CureVac NV Company Profile

Employees
505

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Read More
  • Bafin is already sidekicking asses like they did with WDI and Deutsche Beeeee "oh man"
    0
    • They will announce bankruptcy soon!
      0
      • To all the (american?) Curevac bashers: Learn first about vaccine "business" testings before you write nonsense. The low effective percentage is a result of testing with many many Covid variantions (spread of variants). The high results of MRNA, BNTX, etc. are made with only one Covid variation. But hey... continue talking rubbish - until CVAC comes out with higher percentages for the most dangerous Covid variants.
        2
        • to the moon
          6
          • 12 B Mcap 120 Mio loss each Quater .. 0 Products and the new vaccin failed with 47 % eff. ... sure to the moon ...
            0
        • it is as simple as that: Buy on bad news. Best from Berlin
          3
          • Germans generally worst nation when it comes to investing: If everything is bullish and rising they spreading Germany Angst everywhere and when the markets wiping out the cash and saving profits from previous bull markets they're buying like hell, esp. stocks with neg. news bias like MTU, TKA, WDI, VAR1 or this one here :D
            1
          • Well, your opinion about german invetings you have very exclusively. Blind fish. Lets compare with the US: Germans have faster trains, the best Covid vaccine, better infrastructure, better healthcare system, better food quality, cleaner towns, more renewable energy better public transportation systems, etc. Oh yes, and americans buy much more german cars than Germans buy american. So... what did you say about investing?
            1
          • oh that "statistics" 'were made per capita right like they did it with their alg2? so here is the math 4u: where do most of the German exports go and what German double listings would do without them, 2018 still in mind when most German account holders still n't know that 15 of DAX30 are more Nymex than Eurex and in mid caps even more per title, so for ur nxt level guesses keep the numbers accountable or comparative at least by giving the right relation instead of boosting German ingenuity
            0
        • Yesterday it open at 47, a magical opportunity and now the premarket is 67 and people don't want this stock. are you crazy !!! People talk about bankrut for curevac. You so funny!!!!
          0
          • tomorrow?
            0
            • the same story like Wirecard will bankrupt soon . Sell and take your damage back for ever. Curevac again one more scandal like Wirecard.! German stories.!-(((
              7
              • Haha and the german says, Ex president Trump wanted to buy this ******** :D German liar to advertise yourself
                3
                • lol, market cap 18bln$ with 17mln$ in revenue....
                  0
                  • Exactly, I just wonder why it isn't zero yet
                    0
                • target for CVAC! After this drop I am thinking of gettin in...
                  2
                  • Any chance it cud go bust like Wirecard
                    3
                  • wow, you are brave
                    0
                • Guys , relax and look at this objectivelyit is very hard forecast. anyway i am ok about this situation, because i did not buy this stock
                  2
                  • Man you´re my hero xD
                    0
                  • I sold it a while back
                    0
                • Guys , relax and look at this objectivelyit is very hard forecast. anyway i am ok about this situation, because i did not buy this stock
                  0
                  • Washington Post: CureVac, the latest experimental coronavirus vaccine, proved just 47 percent effective amid spread of variants, preliminary analysis shows
                    0
                    • CureVac will bankrupt soon . forget it sell and run out . On September this CureVac will never exist . big institutions today already sold out in TradeGate .
                      7
                      • still*
                        1
                      • expiry date September 2021 . after you will loose your money sell out to save your capital.
                        0
                      • Because the other vaccines have are higher effective only with a few older variants. They are not tested or went public with results of new dangerous variants. If Curevac would have testet with only 1 or 2 variants like the others have done before... the percentage would be much higher.
                        0
                    • I will add more..nothing changes in the long term outlook
                      5
                      • Serious question: why does nothing change? If they cannot get approval because it is not efficiant, they wont be able to sell their millions and millions of doses which they have already orders for. This cant be good LT. Management did not always take the right decisions in the last year which is not positive either…? How effective is their mrna staff and lab researchers? Hmmm. Having serious doubts here.
                        3
                      • they need 50% to approve - it is 47% now and the trial still in progress. It's for countries which don't have enough vaccines anyway
                        0
                    • Bad news - CureVac (CVAC/5CV GY) says its COVID-19 vaccine demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not achieve prespecified statistical success criteria
                      0
                      • buying time for new entrants..
                        3
                        • oh really?
                          0
                      • From the Motley Fool Germany. Just use Google Translate. https://www.onvista.de/news/curevac-aktie-trader-druecken-den-kurs-fuer-eine-interesssante-langfristige-einstiegschance-464032327
                        1
                        • soon 90..
                          2
                          • not today
                            0
                        • What happens in pre?
                          0
                          • https://finance.yahoo.com/news/eu-regulator-does-not-expect-121745415.html
                            0
                            • thanks
                              0
                          • huge drop today, any news that cause this ?
                            0
                            • approval is 2 month postponed
                              0
                          • what happened?
                            0
                            • https://finance.yahoo.com/news/eu-regulator-does-not-expect-121745415.htmlThe European Medicines Agency (EMA) does not expect to make a decision on the approval of German biotech group CureVac's COVID-19 vaccine before August, an off...
                              0
                          • Approval...this week???
                            2
                            • I hope so.... 🤞
                              0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.